Mobia Medical (MOBI) Director Casey M. Tansey Buys 68,559 Shares

What Happened

• Casey M. Tansey, a director of Mobia Medical, reported multiple open‑market purchases (Form 4) totaling 68,559 shares acquired between August 13 and August 17, 2026. The transactions aggregate to roughly $797,174.
  • Aug 13, 2026 — 35,572 shares at a weighted average price of $11.51 (≈ $409,338). (Footnote F1: underlying trades ranged $11.33–$11.685.)
  • Aug 14, 2026 — 15,721 shares at a weighted average price of $11.65 (≈ $183,150). (Footnote F2: underlying trades ranged $11.42–$12.01.)
  • Aug 14, 2026 — 100 shares at a weighted average price of $12.53 (≈ $1,253). (Footnote F3: underlying trades ranged $11.675–$12.37.)
  • Aug 17, 2026 — 17,166 shares at $11.85 (≈ $203,433).

These are outright purchases (code P), which are purchases of common stock (potentially interpreted as a bullish signal by some investors), not option exercises, awards, or gifts.

Key Details

• Transaction dates: Aug 13, Aug 14, and Aug 17, 2026.
• Reported prices: weighted averages shown above; footnotes F1–F3 disclose that the shares were bought in multiple trades at the price ranges listed in each footnote.
• Total shares acquired: 68,559; total reported cash spent: about $797,174.
• Shares owned after transaction: not specified in the information provided on this Form 4.
• Filing date: Form 4 filed Aug 17, 2026. The Aug 17 trade was reported same day; earlier trades (Aug 13 and Aug 14) were included in this filing — Form 4s are normally due within two business days, so those earlier trades may have been reported after the regulatory deadline (check the filing for a timeliness code if this matters to you).
• No 10b5‑1 plan, tax‑withholding, or gift codes were reported in the data provided.

Context

• These were open‑market purchases (P), meaning shares were bought on the market rather than received as compensation or exercised from options.
• Purchases by directors are often watched by retail investors as a signal of insider confidence, but they do not prove future performance; the filing is factual and does not state motivation.
• Footnotes note the reported prices are weighted averages; the filer offered to provide detailed per-trade price/quantity breakdowns to the issuer, shareholders, or the SEC staff upon request.